UK Shows Problem with Government-Rationed Care
Source: Brian Joondeph, "Death Panels -- Alive and Well," American Thinker, January 16, 2015.
January 20, 2015
Britain's National Health Service has announced that patients will no longer have access to six breast cancer drugs: eribulin, Avastin, Kadcyla, Afinitor, Tyverb and Perjeta. Why? They're expensive, and the country says the cost is not justified.
The Daily Mail reports on the cost of the drugs. For example:
Joondeph says the drug situation in the U.K. illustrates the problem with a government making decisions about what treatment is appropriate for patients and whether medicines are "worth it."
The Daily Mail reports on the cost of the drugs. For example:
- Half of women given eribulin live for more than one year. The drug costs 10,000 pounds for six months of treatment.
- In 55 countries, eribulin is considered "standard care."
Joondeph says the drug situation in the U.K. illustrates the problem with a government making decisions about what treatment is appropriate for patients and whether medicines are "worth it."
No comments:
Post a Comment